Vident Investment Advisory, LLC Biomarin Pharmaceutical Inc Transaction History

Vident Investment Advisory, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $736,744 - $895,162	-10,307 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $33,871 - $42,266	-456 Reduced 4.24%	10,307 $794,000
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $21,013 - $26,800	293 Added 2.8%	10,763 $950,000
Q3 2021 Nov 12, 2021	SELL	$74.77 - $85.47 $46,955 - $53,675	-628 Reduced 5.66%	10,470 $809,000
Q2 2021 Aug 13, 2021	BUY	$75.51 - $84.79 $24,163 - $27,132	320 Added 2.97%	11,098 $926,000
Q1 2021 May 14, 2021	BUY	$74.73 - $90.69 $35,272 - $42,805	472 Added 4.58%	10,778 $814,000
Q4 2020 Feb 08, 2021	BUY	$72.61 - $90.2 $228,431 - $283,769	3,146 Added 43.94%	10,306 $903,000
Q3 2020 Nov 12, 2020	BUY	$71.87 - $131.03 $85,812 - $156,449	1,194 Added 20.01%	7,160 $545,000
Q2 2020 Jul 17, 2020	BUY	$79.55 - $124.22 $474,595 - $741,096	5,966 New	5,966 $736,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.